Intralesional methotrexate (MTX) could to be promising conservative alternative for non-melanoma skin cancer (NMSC). Systemic MTX was attempted as adjuvant for locally-advanced NMSC.
to compare the effectiveness and safety of intralesional vs. systemic MTX in NMSC management